tumor-activated drug conjugate development

Duo Oncology is a clinical-stage company developing tumor-activated drug conjugates designed to transform toxic multi-agent chemotherapy regimens into single medicines that concentrate therapeutic activity in tumors while limiting healthy-tissue exposure. Its lead clinical-stage product, DUO-207, combines gemcitabine and paclitaxel into a single-infusion, tumor-metabolized conjugate intended as a next-generation chemotherapy backbone for the KRAS inhibitor era.

Read more

clinical trial development (Phase 1b/2)GLP toxicology studiespreclinical pharmacology